Clearmind Medicine Inc.
$1.14
0%
2026-04-21 06:06:01
www.clearmindmedicine.com
NCM: CMND
Explore Clearmind Medicine Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.38 M
Current Price
$1.14
52W High / Low
$52.4 / $0.59
Stock P/E
—
Book Value
$5.49
Dividend Yield
—
ROCE
-475.2%
ROE
-1.2%
Face Value
—
EPS
$-24.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
-1.03
Debt / Equity
0.1
Current Ratio
3.79
Quick Ratio
1.22
Forward P/E
—
Price / Sales
—
Enterprise Value
$-7.67 M
EV / EBITDA
0.98
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Onconetix, Inc. | $0.73 | — | $0.51 M | — | -40.18% | -1.15% | $74.3 / $0.67 | $50.53 |
| 2. | Rein Therapeutics Inc. | $1.83 | — | $51.31 M | — | -121.99% | -1.4% | $2.4 / $1.02 | $-1.02 |
| 3. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
| 4. | Cellectar Biosciences, Inc. | $2.95 | — | $12.21 M | — | -224.66% | -1.7% | $20.7 / $2.43 | $1.89 |
| 5. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
| 6. | Apollomics, Inc. | $13.53 | — | $15.34 M | — | -737.55% | -3.8% | $42.12 / $3.66 | $-3.99 |
| 7. | Enliven Therapeutics, Inc. | $46.41 | — | $2.88 B | — | -26.04% | -26.95% | $48.53 / $14.79 | $7.73 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.66 M | -1.46 M | -1.41 M | -1.31 M | -1.5 M | — |
| Net Profit | -3.85 M | -0.69 M | -1.31 M | -0.78 M | -1.07 M | — |
| EPS in Rs | -1.61 | -0.29 | -0.55 | -0.33 | -0.45 | -23.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -5.67 M | -5.74 M | -6.3 M | -6.25 M |
| Net Profit | -3.86 M | -5.25 M | -8.62 M | -6.89 M |
| EPS in Rs | -1.61 | -2.19 | -3.6 | -2.88 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.08 M | 7.26 M | 5.95 M | 0.83 M |
| Total Liabilities | 4.89 M | 4.15 M | 4.97 M | 1.93 M |
| Equity | 1.19 M | 3.11 M | 0.98 M | -1.11 M |
| Current Assets | 5.95 M | 7.09 M | 5.79 M | 0.43 M |
| Current Liabilities | 4.89 M | 4.13 M | 4.97 M | 1.93 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.73 M | -4.86 M | -6.3 M | -3.72 M |
| Investing CF | -0.54 M | -0.24 M | -0.03 M | -0.01 M |
| Financing CF | 2.62 M | 6.25 M | 11.66 M | 0.51 M |
| Free CF | -4.73 M | -4.86 M | -6.3 M | -3.73 M |
| Capex | — | — | — | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 39.05% | -25.03% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-12-15 | 1:0.025 |
| 2023-11-28 | 1:0.0333333 |